CO-Diagnostics Inc (NASDAQ:CODX) Reports Mixed Q2 2025 Earnings with Revenue Beat but Persistent Losses Co-Diagnostics (CODX) Q2 2025 earnings show revenue beat at $160K but EPS loss of -$0.23. Shares flat post-report as investors await profitability signs.
Thursday's pre-market session: top gainers and losers The US market session of Thursday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
Stay updated with the stocks that are on the move in today's pre-market session. Discover the top movers in Friday's pre-market session and stay informed about market dynamics.
These stocks are moving in today's after hours session As the regular session of the US market on Monday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Top movers in Tuesday's after hours session Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
Penny Stock Co-Diagnostics Withdraws FDA Application For COVID-19 Test, Plans To Submit Enhanced Version Co-Diagnostics plans to submit an enhanced COVID-19 test for FDA clearance, addressing stability concerns and integrating platform advancements.
CODX Stock Earnings: Co-Diagnostics Beats EPS, Beats Revenue for Q2 2024 CODX stock results show that Co-Diagnostics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
CODX Stock Earnings: Co-Diagnostics Misses EPS, Misses Revenue for Q1 2024 CODX stock results show that Co-Diagnostics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
